2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.22: Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center

Pdf Summary

The study investigates the association between tobacco smoking and clinical and molecular characteristics of KRAS-mutated non-small cell lung cancer (NSCLC) at the Stanford Cancer Institute. KRAS mutations are present in about 25% of NSCLC cases and are often linked to a history of smoking. This retrospective study analyzed patients identified from the STAnford Research Repository with follow-up between December 2010 and June 2024. Inclusion criteria included a histologic diagnosis of NSCLC and the presence of at least one pathogenic KRAS mutation.<br /><br />Patient demographics showed significant differences in age, sex, and race/ethnicity among smokers and non-smokers. Smokers were more likely to be older, male, and white compared to non-smokers. However, no significant distinctions were observed in tumor histology or disease stage between the two groups.<br /><br />The study assessed survival outcomes, including overall survival from diagnosis and initiation of immunotherapy, and progression-free survival from the start of immunotherapy. Results indicated that smoking status influenced clinico-molecular profiles but was not a significant prognostic marker for survival outcomes in this patient subset.<br /><br />Among different KRAS mutation subtypes, variations were noted in frequency based on smoking status, though detailed molecular profiling remains recommended irrespective of tobacco history to tailor treatment optimally. Despite the smoking history's role in defining clinical and molecular characteristics, its lack of prognostic value suggests broader molecular profiling is essential in targeted treatment strategies.<br /><br />In conclusion, while tobacco use is linked to specific differences in patients with KRAS-mutated NSCLC, smoking alone does not serve as a reliable predictor of patient prognosis or treatment outcomes. Comprehensive molecular analysis is necessary to inform treatment decisions.

Asset Subtitle

Jacqueline Aredo

Keywords

tobacco smoking

KRAS-mutated NSCLC

Stanford Cancer Institute

non-small cell lung cancer

patient demographics

survival outcomes

molecular profiling

prognostic marker

treatment strategies

clinical characteristics